Gagnon Securities LLC Sells 26,871 Shares of T2 Biosystems Inc (TTOO)
Gagnon Securities LLC decreased its holdings in T2 Biosystems Inc (NASDAQ:TTOO) by 28.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 67,360 shares of the medical equipment provider’s stock after selling 26,871 shares during the quarter. Gagnon Securities LLC’s holdings in T2 Biosystems were worth $278,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Lagoda Investment Management L.P. raised its stake in T2 Biosystems by 61.4% in the third quarter. Lagoda Investment Management L.P. now owns 3,188,539 shares of the medical equipment provider’s stock worth $13,392,000 after buying an additional 1,212,618 shares in the last quarter. Senvest Management LLC raised its stake in T2 Biosystems by 17.6% in the third quarter. Senvest Management LLC now owns 3,337,946 shares of the medical equipment provider’s stock worth $14,019,000 after buying an additional 500,000 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of T2 Biosystems during the third quarter worth $630,000. Finally, Geode Capital Management LLC increased its position in shares of T2 Biosystems by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 134,470 shares of the medical equipment provider’s stock worth $554,000 after purchasing an additional 39,722 shares in the last quarter. 59.67% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on TTOO. HC Wainwright set a $8.00 price target on T2 Biosystems and gave the stock a “buy” rating in a research report on Monday, February 12th. Zacks Investment Research downgraded T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Finally, Goldman Sachs Group began coverage on T2 Biosystems in a research report on Monday, January 29th. They set a “neutral” rating and a $5.20 price target on the stock. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.56.
T2 Biosystems Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Want to see what other hedge funds are holding TTOO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for T2 Biosystems Inc (NASDAQ:TTOO).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.